Natural infection induces a cellular and humoral immune response to the varicella-zoster virus, which can be rapidly detected following infection. IgG, IgM and IgA directed against viral proteins usually appear at the same time that a cellular immune response can be demonstrated, making the relative contribution of humoral and cellular immunity to disease progression difficult to ascertain. Vaccination has been shown to induce both humoral and cell-mediated types of immunity.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
ATC code | Group title | Classification |
---|---|---|
J07BK01 | Varicella, live attenuated | J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BK Varicella zoster vaccines |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Title | Information Source | Document Type | |
---|---|---|---|
VARILRIX Powder and solvent for solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Varicella, live attenuated is an active ingredient of these brands:
Austria (AT)
Brazil (BR)
Canada (CA)
Cyprus (CY)
Estonia (EE)
Hong Kong (HK)
Ireland (IE)
Italy (IT)
Lithuania (LT)
Malta (MT)
New Zealand (NZ)
Poland (PL)
Singapore (SG)
South Africa (ZA)
Turkey (TR)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.